MSD discontinues Phase III BELLWAVE-011 trial of nemtabrutinib
MSD (Merck & Co) halted its Phase III BELLWAVE-011 trial of nemtabrutinib for leukaemia after an external review found potential risks outweighed benefits. The company also terminated the wider BELLWAVE program, including two other Phase III trials. MSD plans to share full findings and continue developing treatments for blood cancers. According to GlobalData, CLL/SLL cases in major markets are expected to rise to 478,279 by 2032.
How this was made
The 30-second read
Why it matters
An eDMC review led MSD to permanently discontinue nemtabrutinib development across the entire clinical programme, including termination of two additional Phase III trials (BELLWAVE-008 and BELLWAVE-010). This is a direct de-risking event for the asset and reduces near-to-mid-term probability of positive Phase III outcomes.
Market read
Traders should reassess the probability-weighted value of MSD’s nemtabrutinib Phase III pipeline and the timing of future haematology catalysts, given the permanent discontinuation decision.
What to watch
The article does not provide efficacy or safety metrics, so traders may overreact until MSD shares detailed dataset findings and any implications for other BTK or B-cell receptor pathway programs.
Background
Nemtabrutinib (MK-1026) is an investigational, oral non-covalent BTK inhibitor being tested in CLL/SLL and other haematologic malignancies under the BELLWAVE Phase III program.
Ticker impact
MSD (Merck & Co) discontinued its Phase III BELLWAVE-011 nemtabrutinib program after an eDMC review, halting the broader BELLWAVE Phase III pipeline.
Likely downward pressure as investors price in reduced probability of future clinical success and potential write-downs or reallocation of R&D resources.
The article states MSD permanently halted Phase III development of nemtabrutinib and terminated additional Phase III trials (BELLWAVE-008 and -010), which is a direct, company-specific clinical de-risking event.
Market effects
BTK inhibitor development risk is highlighted, potentially pressuring sentiment around similar fixed-duration CLL/SLL regimen strategies.
No direct regional macro catalyst; impact is primarily company and sector-specific.
Global haematology/oncology investors may reassess probability-weighted outcomes for next-gen BTK programs.
Counterpoint
The eDMC conclusion may reflect a specific risk-benefit imbalance in BELLWAVE-011, while other pipeline assets or combinations could still progress without implying broad platform failure.
Key entities
- companyMSD (Merck & Co)
Sponsor that discontinued the Phase III BELLWAVE-011 trial and terminated additional Phase III nemtabrutinib studies after eDMC review.
- drugnemtabrutinib (MK-1026)
Investigational non-covalent BTK inhibitor whose Phase III development was halted.
- committeeeDMC (external Data Monitoring Committee)
Reviewed trial data and advised that clinical advantages might not outweigh observed patient risks.
- clinical_trialBELLWAVE-011 (NCT06136559)
Phase III trial in CLL/SLL and other haematologic malignancies that was discontinued.
- clinical_trialBELLWAVE-008 (NCT05624554) and BELLWAVE-010 (NCT05947851)
Additional Phase III trials terminated as part of the broader programme halt.




